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Abstract
Background: DNA-methyltransferase-3B (DNMT3B), which plays a role in DNA methylation, is
usually aberrant expression involved in carcinogenesis. Polymorphisms of the DNMT3B gene may
influence DNMT3B activity on DNA methylation in several cancers, thereby modulating the
susceptibility to cancer.
Methods:  DNMT3B -579G>T genotypes and -149C>T were determined by PCR-RFLP and
sequencing in 137 colorectal cancer patients and 308 controls matched for age and sex, who did
not receive radiotherapy or chemotherapy for newly diagnosed and histopathologically confirmed
colorectal cancer. The association between two SNPs of the DNMT3B promoter and the risk of
the development of colorectal cancer was analyzed in a population of Chinese.
Results: The allele frequency of -149C >T among patients and controls was 0.73% versus 0.65%,
respectively. The allele frequency of -597G>T for patients and controls was 6.57% versus 11.53%,
respectively. Individuals with at least one -149C>T allele were no at a significantly increase risk of
colorectal cancer compared with those having a -149TT genotype. However, Individuals with at
least one 579G>T allele were decreased risk of colorectal cancer compared with those having a -
579TT genotype.
Conclusion: The relative distribution of -149C>T DNMT3B SNPs among a Chinese population can
not be used as a stratification marker to predict an individual's susceptibility to colorectal cancer.
However, the DNMT3B -579G>T polymorphism may contribute to the genetic susceptibility to
colorectal cancer.
Background
Single nucleotide polymorphisms (SNPs) are the most
common form of human genetic variation, and may con-
tribute to an individuals' susceptibility to cancer. Some
studies have suggested that some variants in the promoter
regions of genes may affect either the expression or activ-
ity levels of enzymes [1-3] and therefore may be mecha-
nistically associated with cancer risk. DNA methylation is
a major epigenetic modification involving the addition of
a methyl group to the 5' position of a cytosine in a CpG
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dinucleotide. A number of studies have suggested that
aberrant DNA cytosine methylation may play an impor-
tant role in carcinogenesis [4-8]. DNMT3a and DNMT3b
are required for the establishment and maintenance of
genomic methylation patterns and proper murine devel-
opment [9-12]. Both genes are up-regulated to differing
degrees in some malignancies, including esophagus carci-
noma, lung cancer and colorectal cancer [13-18].
Recently, several studies showed that some of SNPs in the
DNMT3B gene may influence DNMT3B activity on DNA
methylation, thereby modulating the susceptibility to
lung cancer, breast cancer and gastric cardiac adenocarci-
noma [14,19,20]. The DNMT3B gene contains a single
C>T transition polymorphism (C46359T, GenBank acces-
sion no. AL035071) in the promoter region of the
DNMT3B  gene, -149 base pairs from the transcription
start site, is reported to greatly increase promoter activity
[21]. Some reports have shown that the C/T polymor-
phism is associated with an increased risk for lung cancer
and carcinoma of the head and neck. Carriers of T allele,
particularly heterozygotes, have a significantly increased
risk for such cancers[2,22-24]. However, C/T polymor-
phism is not associated with the increased risk of hapeto-
cellular carcinoma (HCC) and gastric cancer, especially in
Chinese. Another G>T SNP of DNMT3B gene, in the tran-
scription start site of the promoter region (-579 bp from
exon 1B, GenBank accession no. NT_028392) and this
probably affects gene function [2]. Some studies have sug-
gested that the DNMT3B -579 G>T may modify suscepti-
bility to tumors, although conflicting results have been
reported in different tumor types, the heterozygous geno-
type have been reported to have a significantly reduced
risk of developing lung and colorectal cancer [25-27], but
DNMT3B genetic polymorphism is variable in different
races, ethnic groups or geographic areas. In the present
study, we evaluated the association of _149C>T and
_579G>T polymorphisms with colorectal cancer in Chi-
nese population.
Methods
Study population
This case-control study included 137 colorectal cancer
and 308 healthy controls, and the informed consent was
obtained. The 137 case subjects were patients who had
undergone surgery and been histopathologically con-
firmed at the Zhongda Hospital of Southeast University
and Tumor Hospital, Nanjing, China. The control subjects
were selected from a pool of cancer-free subjects who vis-
ited the same hospital for a regular physical examination
and who volunteered to join the epidemiology survey
during the same period. We defined a healthy subject as a
person free of disease (including no history of cancer) on
health check-up. They were matched with the case
patients by age and sex (Table 1). All cases and controls
were ethnically Chinese and resided in Jiangsu province
or in the surrounding regions.
DNA extraction
5 milliliters of venous blood from each subject was drawn
in vacuum tubes containing EDTA and stored at 4°C.
Genomic DNA was extracted within one week after sam-
pling by using proteinase K digestion followed by a salting
out procedure [28].
DNMT 3B genotyping
The transition of C/T of DNMT3B  SNP creates a BlnI
restriction site and the transition from G to T of the
DNMT3B SNP creates a PvuII restriction site, which could
be exploited for genotyping by PCR and subsequent
restriction fragment length polymorphism (RFLP) analy-
sis. PCR was performed in a volume of 25 μL containing
100 ng of DNA template, 10 × PCR master mix (Promega,
USA), and 10 pmol/L each of sense primer (5'-
TGCTGTGACAGGCAGA2GCAG-3') and antisense primer
(5'-GGTAGCCGGGAACTCCACGG-3') for _149C>T, and
sense primer (5'-GAGGTCTCATTATGCCTAGG-3') and
antisense primer (5'-GGGAGCTCACCTTCTAGAAA-3')
for _579G>T. For PCR amplification, an initial denatura-
tion step at 94°C for 5 min was followed by 30 cycles at
94°C for 30 s, 57°C for 30 s, and 72°C for 30 s, and a final
extension step at 72°C for 7 min. Subsequently, the PCR
products were digested overnight with Blnl (TaKaRa) 4 U
for 149C>T and 5 units of PvuII (New England Biolabs,
Beverly, Mass.) for 579G>T at 37°C, respectively, and the
products separated on 2% agarose gels. RFLP bands were
visualized by ethidium bromide staining under UV light.
The 149C>T polymorphism depend upon the existence of
the Blnl recognizing site, the DNMT3B T/T genotype was
expected to show two DNA bands at the positions of 207
and 173 bp, the C/C genotype was expected to show a sin-
gle band (380 bp), while the heterozygote was expected to
have three bands (380, 207 and 173 bp). The 579G>T pol-
ymorphism was determined by PvuII. The wild-type G
allele has only one band, while the polymorphic T allele
has two bands (132 and 93 bp). For quality control, gen-
otyping analysis was performed blind with respect to case/
control status and repeated twice for all subjects. The
results of genotyping were 100% concordant. To confirm
the genotyping results, selected PCR-amplified DNA sam-
Table 1: Characteristics of the study population.
Variables Case (n = 137) Control (n = 308)
Ages (years)* 65 71
Sex
Male 91 206
Female 46 102
* p > 0.05Journal of Experimental & Clinical Cancer Research 2008, 27:24 http://www.jeccr.com/content/27/1/24
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ples (n = 3, respectively, for each genotype) were exam-
ined by DNA sequencing, and the results were also 100%
concordant.
Statistical analysis
Cases and controls were compared using Student's t-test
for continuous variables and the X2 test for categorical var-
iables. Hardy – Weinberg equilibrium was tested with a
goodness-of-fit X2 test with one degree of freedom to com-
pare the observed genotype frequencies with the expected
genotype frequencies among the subjects. Comparison of
the DNMT3B genotype and allelotype distribution in the
study groups was performed by means of two-sided con-
tingency tables using X2 test or Fischer's exact test. The
odds ratio (OR) and 95% confidence interval (CI) were
calculated using an unconditional logistic regression
model and adjusted by age and gender accordingly. P <
0.05 was considered statistically significant.
Results
The demographics of the cases and controls enrolled in
this study are shown in Table 1. There were no significant
differences in the mean age and sex distribution between
cases and controls, suggesting that the matching based on
these two variables was adequate. There was no evidence
of a deviation from Hardy-Weinberg equilibrium among
the case or control subjects. The mean age was 65 years
(range, 34 – 80 years) for the case patients and 71 years
(range, 32 – 80 years) for the control subjects (Table 1).
All patients and controls were successfully genotyped for
the  DNMT3B  polymorphism. The genotyping by PCR-
RFLP analysis was completely confirmed by DNA
sequencing analysis, and the results of PCR-RFLP genotyp-
ing and sequencing analysis were also 100% concordant
(Fig. 1). The distribution of the 149C>T and the 579G>T
polymorphism of DNMT3B  were in Hardy-Weinberg
equilibrium. The distributions of DNMT3B 149C>T and
579G>T genotypes among controls and cases are shown
in Table 2. The allele frequency of 149C>T among patients
and controls was 0.73% versus 0.65%, respectively. The
allele frequency of 579G>T for patients and controls was
6.57% versus 11.53%, respectively. No significant devia-
tion was observed for the genotype distributions of
149C>T polymorphisms between colorectal cancer cases
and controls. However, the distributions of 579G>T gen-
otypes in the colorectal cancer group (GG 0%, GT
13.14%, TT 86.86) were significantly different from those
among the controls (GG 1.95%, GT 19.15%, TT 78.90%;
0.01 < P < 0.05).
The colorectal cancer risk related to the DNMT3B 149C>T
and 579G>T genotypes were shown in table 3. ORs and
their 95% CIs were calculated using the more common
homozygous variant genotype as the reference group
(149TT and 579 TT genotypes, respectively). Because of
low prevalence of homozygous wild-type genotype, we
combined this genotype with heterozygous genotype into
one group and compared it with the reference group. As
compared with the reference group, the combined 149CC
Sequencing results for each of the PCR products from -149 C>T (A) and -579 G>T (B) Figure 1
Sequencing results for each of the PCR products from -149 C>T (A) and -579 G>T (B). Sequencing results for each 
of the PCR products from -149 C>T (A) and -579 G>T (B), the SNP sites are as indicated by the arrowhead. These results 
were completely matched to corresponding results deriving from PCR-RFLP by agarose gel genotyping method.Journal of Experimental & Clinical Cancer Research 2008, 27:24 http://www.jeccr.com/content/27/1/24
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and CT genotype, were associated with non-significant
increased of colorectal cancer (OR = 1.13; 95% CI = 0.20–
6.22). However, as compared with the reference group,
the combined 579 GG and GT genotype, were associated
with significant decreased of colorectal cancer (OR = 0.57
95% CI = 0.32–1.00). Then we stratified the results by age,
patients and controls were found to be a little different
with respect to the genotype distribution. Our data thus
reveal that the presence of 579 G>T rather than 149 C>T
exists significance likelihood of carcinogenesis for color-
ectal cancer patients, at least in a Chinese population. The
results didn't show that 597 G>T is associated with the
onset age of CRC in this study.
Discussion
Colorectal cancer (CRC) is one of the most common can-
cers, with an estimated worldwide incidence of more than
570,000 new cases per year [29]. Despite recent surgical,
radiotherapy and chemotherapy advances in the treat-
ment protocol, the long-term survival of CRC patients still
remains at approximately 50% for the past three decades.
Early detection among susceptible populations has been
advocated to decrease both the morbidity and the mortal-
ity of CRC, but searching for a useful stratification marker
to predict its genetic susceptibility still would appear to
impose a major challenge for CRC researchers.
DNA methylation has been reported to play a significant
role in the development and progression of various can-
cers. In such cases, DNA methylation is typically mediated
by DNA methyltransferases (DNMTs), specifically
DNMT1, DNMT3A and DNMT3B. DNMT1 is considered
as a maintenance DNA methyltransferase due to its ability
to preferentially methylate hemimethylated DNA subse-
quent to DNA replication [30,31]. DNMT3A  and
DNMT3B function as de novo methyltransferases, which
reportedly methylate unmethylated and hemimethylated
DNA with equal efficiencies [32].
A single nucleotide polymorphism (SNP) of the DNMT3B
promoter polymorphism -149 C>T, have recently been
shown increase susceptibility of an individual to lung can-
cer [2], breast cancer [23] and significantly associated with
increased age-associated risk in HNPCC families [24], but
not to head and neck squamous cell carcinoma in Taiwan-
ese [33], HCC [34] and gastric cardiac adenocarcinoma in
Chinese [35], and gastric cancer in a Japanese population
[36]. Another single nucleotide polymorphism (SNP) of
the DNMT3B promoter 579G > T is from exon 1B tran-
scription start site of DNMT3B. Although it is supposed
probably affect the gene function [27], the 579 G>T poly-
morphisms did not significantly change the promoter
activity of DNMT3B by luciferase assay [26]. However,
studies recent been shown decrease susceptibility of an
individual to lung cancer [2] and colon cancer [27]. These
data suggested that DNMT3B promoter 579G > T poly-
morphism can be used a risk factor of cancer to evaluate
the population susceptible to tumors. Some other study
haven't shown association between polymorphism of
579G > T and head and neck squamous cell carcinoma
[33], and esophagus cancer [37].
In the current study, we investigated the influence of
DNMT3B polymorphisms -149 C>T and -579G > T on the
risk of colorectal cancer in a hospital-based case-control
study in a Chinese population. For -149 C>T, CC geno-
type was not detectable in both CRC patients and con-
trols, while the T allele was predominant just like in a
Taiwanese population [33] and a Japanese population
[36]. There was no significant difference between CRC
patients and control in -149 C>T of DNMT3B polymor-
phisms. These data implied that, an individual with the -
149C>T polymorphism has not an increased susceptibil-
ity to CRC cancer in the study Chinese population. How-
Table 2: DNMT3B genotypes and allele frequency among controls and cases
-149 C > T genotype -579G.>T genotype
CC CT TT C alleleb
frequency (%)
GG GT TT G allelec 
frequency (%)
Control 0(0.00) 4(1.30) 304(98.70) 0.65 6(1.95) 59(19.15) 243(78.9) 11.53
Case 0(0.00) 2(1.46) 135(98.54) 0.73 0(0.00) 18(13.14) 119(86.86) 6.57
aNumbers in parentheses, percentage.
bp > 0.05
c0.01 <p < 0.05
Table 3: Crude and adjusted ORs for colorectal cancer 
associated with DNMT3B genotypes
Genotypes Cases
-149 T>C genotype
TT (reference) 1.00
TC +CC crude 1.13 (0.20–6.22)
-579 G.>T genotype
TT (reference) 1.00
GT + GG crude 0.57(0.32–1.00)Journal of Experimental & Clinical Cancer Research 2008, 27:24 http://www.jeccr.com/content/27/1/24
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ever, carriers with 579G allele were at decreased risk of
CRC as compared with individuals having 579T alleles.
This finding suggests that the 579G>T polymorphism in
the DNMT3B gene could be used as a marker of genetic
susceptibility to CRC cancer.
Our findings are consistent with those of studies, which
showed that individuals carrying the G allele have a signif-
icantly lower risk of developing adenocarcinoma of the
lung cancer [2] and colon cancer [27]. Carriers with the G
allele in the DNMT3B  gene were found to have a
decreased risk of colon cancer compared with individuals
with the T allele. These findings implied that the DNMT3B
polymorphism might operate in a tissue-specific manner,
especially in colorectal tissue. However, this finding needs
to be confirmed by a larger study. The present result, and
those from lung and colon cancer which are the only pub-
lished data on association between DNMT3B SNP and
cancer development, can show the different possible roles
of  DNMT3B  in different cell types. Since the different
splice variants of DNMT3B which may alter catalytic activ-
ity are expressed in a tissue specific manner [10,38-40]
and repression of DNMT3B activity does not result in the
re-expression of all hypermethylated tumor suppressor
genes in some cell system [41-44], it is therefore impor-
tant to explore the complex interplay of DNMTs in differ-
ent tumor types. Since genetic polymorphisms often vary
between ethnic groups, further studies are needed to clar-
ify the association of the DNMT3B polymorphism with
colorectal cancer in diverse ethnic populations. Future
studies of other DNMT3B sequence variants and their bio-
logic function are also needed to understand the role of
DNMT3B polymorphisms in determining the risk of can-
cer.
Conclusion
The DNMT3b -579G>T polymorphism may contribute to
the genetic susceptibility to colorectal cancer. Carriers
with the G allele in the DNMT3B gene were found to have
a decreased risk of colorectal cancer compared with indi-
viduals with the T allele. However, the relative distribu-
tion of -149C>T DNMT3B  SNP among a Chinese
population can not be used as a stratification marker to
predict an individual's susceptibility to colorectal cancer.
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